HR+/HER2- Breast Cancer Market Set To Triple

The HR-positive/HER2-negative breast cancer market is set to more than triple in value by 2022, according to a new forecast by Datamonitor Healthcare. The growth will be driven by a marketed product as well as the approval of several late-phase pipeline candidates. Generic and biosimilar drugs are expected to offset these sales from the beginning of 2023.

The hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer market was worth $3.4bn across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) in 2015, according to new Datamonitor Healthcare estimates. This figure is forecast to steadily increase, reaching a peak of $10.7bn in 2022 before falling back down to $9.6bn in 2024.

Despite the drop off in the last two years of the forecast, the market is projected to increase at a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By 

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

More from Therapy Areas

Bristol Myers Shifts Five Drugs To Bain-Partnered Immunology Venture

 
• By 

Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.